Gastric Cancer

NSUN2-mediated m5C modification of EPYC contributed to GC cell growth and metastasis, which provided a novel regulatory axis for understanding the pathogenesis of GC.

Moreover, BB-1701, a novel HER2-ADC containing eribulin as a payload, to which N87 AR cells are sensitive, exhibited antitumor effects in N87 AR cells in vitro and in vivo. These findings indicate that ABC transporter-mediated drug efflux is an important mechanism underlying T-DXd resistance in HER2-positive gastric and lung cancer models. Furthermore, our study suggests that both targeting drug efflux pathways and utilizing alternative payloads may be effective strategies for overcoming T-DXd resistance in HER2-positive gastric and lung cancers.

Additionally, it functions as a novel "metabolic immune checkpoint" across multiple cancer types. SPHK1 may bridge sphingolipid metabolism with tumor immune suppression and represents a potential promising integrated target for metabolically informed immunotherapy strategies.

A deep learning model based on iodine map has been proven to be a valuable, reliable, and interpretable tool for non-invasive prediction of PD-L1 expression in GC.

Short-term outcome of pharmacological conservative treatment after bowel obstruction in malignant tumors of the digestive system influences patients' long-term survival but is not an independent prognostic factor. Staging and previous tumor surgery are independent prognostic factors influencing survival in patients with malignancies of the digestive system combined with bowel obstruction.

The ROS scavenger N-acetyl-l-cysteine reversed isovanillin-induced protein expression changes. In conclusion, isovanillin induces apoptosis, G2/M phase arrest, and inhibits MKN-45 cell migration by mediating ROS to regulate the MAPK and PI3K signaling pathways.

CEA declined from 71.9 to 3.5 ng/mL within 2 months post-irradiation. One-year post-radiotherapy, a gradual CEA increase together with FDG-PET/CT and MRI findings suggested local recurrence;nevertheless, disease activity remained contained while the super-elderly patient retained independent activities of daily living.

The overall survival was 14.9 months for all patients, 31.5 months for 3 patients, including 2 patients who had a history of nivolumab and 1 patient who was HER2 positive and had only brain and meningeal dissemination as distant metastases, and 3.0 months for the other 3 patients(p=0.025). In addition to local therapy, immune checkpoint inhibitors and molecular targeted drugs may be effective in treating gastric cancer with brain metastasis.

This case demonstrates the potential of ICI-combined chemotherapy in achieving pCR in MSI-high, HER2-negative unresectable gastric cancer. Accumulation of similar cases is needed to establish optimal postoperative management strategies.

In this report, we present a case of gastric Schwannoma that demonstrated a tendency to increase in size and was successfully treated with laparoscopic local resection. We also include a discussion of relevant literature.

Because of HER2 negative, 2 courses of ramucirumab plus paclitaxel was administered, but lung metastasis, increased liver metastasis, and ascites were detected...Nivolumab treatment was continued, and there has been no further disease progression at 83 months post-surgery. This case shows that disease control was achieved with nivolumab for liver, lung, and lymph node metastases following gastric cancer surgery, and long-term survival was attained with multimodal therapy.

P1/2, N=66, Recruiting, Lumicell, Inc. | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Dec 2025 --> Dec 2026